Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Schafer CM, Gurley JM, Kurylowicz K, Lin PK, Chen W, Elliott MH, Davis GE, Bhatti F, Griffin CT. An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression. Proc Natl Acad Sci U S A. 2020 10 20; 117(42):26494-26502.
-
Wallace DK, Kraker RT, Freedman SF, Crouch ER, Bhatt AR, Hartnett ME, Yang MB, Rogers DL, Hutchinson AK, VanderVeen DK, Haider KM, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Kong L, Cotter SA, Holmes JM. Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity. JAMA Ophthalmol. 2020 06 01; 138(6):698-701.
-
Chase D, Huang HQ, Monk BJ, Ramondetta LM, Penson RT, Gil K, Landrum LM, Leitao M, Oaknin A, Huh WK, Pulaski HL, Robison K, Guntupalli SR, Richardson D, Salani R, Sill MW, Wenzel LB, Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
-
Wade KNS, Brady MF, Thai T, Wang Y, Zheng B, Salani R, Tewari KS, Gray HJ, Bakkum-Gamez JN, Burger RA, Moore KN, Bookman MA. Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218. Gynecol Oncol. 2019 10; 155(1):69-74.
-
Invernizzi A, Nguyen V, Teo K, Barthelmes D, Fung A, Vincent A, Gillies M. Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019 08; 204:105-112.
-
Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
-
Palavalli Parsons LH, Roane B, Manders DB, Richardson DL, Kehoe SM, Carlson M, Miller DS, Lea JS. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.
-
Beckham TH, Romesser PB, Groen AH, Sabol C, Shaha AR, Sabra M, Brinkman T, Spielsinger D, McBride S, Tsai CJ, Riaz N, Tuttle RM, Fagin JA, Sherman EJ, Wong RJ, Lee NY. Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid. 2018 09; 28(9):1180-1189.
-
Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252.
-
Qiu F, Shin Y, Chen D, Cheng R, Chen Q, Zhou K, Larrick JW, Mendelson AR, Ma JX. Anti-angiogenic effect of a humanized antibody blocking the Wnt/ß-catenin signaling pathway. Microvasc Res. 2018 09; 119:29-37.